Login to Your Account

Financings Roundup

Latest IPO Filing Sees HCV Player Enanta Seeking $69M

By Catherine Shaffer
Staff Writer

Thursday, November 8, 2012

Enanta Pharmaceuticals Inc., of Watertown, Mass., filed with the SEC an S-1 for an initial public offering (IPO) worth $69 million to support its work in the area of hepatitis C virus (HCV).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription